The Advanced Transdermal Delivery (ATD) Gel System is responsible for the enhanced bioavailability of Anturol (oxybutynin), Elestrin (estradiol), LibiGel (testosterone), the Nestorone and estradiol ATD contraceptive and JZP-7 the ropinirole formulation (partnered with Jazz Pharmaceuticals).
Dario Carrara, Antares Pharma’s senior vice president and managing director of the Pharmaceutical Group, said: “The issuance of this patent is an important achievement in the strengthening of company’s intellectual property portfolio. This second extension demonstrates the potential flexibility of our ATD system technology to accommodate difficult to deliver drugs for the treatment of conditions such as pain, migraines, nauseas and neuro-degenerative disorders.”